EyePoint Pharmaceuticals (EYPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a $22.00 price target.
Yi Chen has given his Buy rating due to a combination of factors that highlight EyePoint Pharmaceuticals’ promising future prospects. The company is making significant progress in its Phase 3 trials for DURAVYU in wet AMD, with enrollment exceeding expectations and completion anticipated in the second half of 2025. This progress suggests potential for successful outcomes, which could enhance the company’s market position.
Additionally, EyePoint Pharmaceuticals has reported positive results from its Phase 2 VERONA trial for DURAVYU in diabetic macular edema, demonstrating a substantial reduction in treatment burden and improvements in visual acuity and central subfield thickness. With a strong cash position expected to sustain operations into 2027 and no immediate plans to raise additional capital, the company is well-positioned financially to continue its development programs. These factors collectively support the Buy rating and a price target of $22.
According to TipRanks, Chen is an analyst with an average return of -17.5% and a 29.90% success rate. Chen covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, AngioDynamics, and Veru.
In another report released yesterday, Scotiabank also maintained a Buy rating on the stock with a $18.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com